Xenetic Biosciences, Inc. 8-K

What Happened
Xenetic Biosciences, Inc. announced that on April 21, 2026 its Compensation Committee approved a restricted stock award of 100,000 shares to James Parslow, who serves as the Company’s Interim Chief Executive Officer and Chief Financial Officer. The award was made under the company’s Amended and Restated Equity Incentive Plan and is documented in a grant agreement filed with the 8-K.

Key Details

• Grant size: 100,000 restricted shares awarded to James Parslow.
• Vesting schedule: 7,000 shares vested on grant date (April 21, 2026); the remaining 93,000 shares vest in three equal annual installments of 31,000 shares on the first, second and third anniversaries of April 21, 2026 (i.e., Apr 21, 2027; Apr 21, 2028; Apr 21, 2029).
• Approved by: Compensation Committee of the Board of Directors.
• Agreement filed: Restricted Stock Award Agreement included as Exhibit 10.1 to the 8-K.

Why It Matters
This filing documents compensation granted to Xenetic’s interim top executive and finance head, aligning his interests with shareholders through equity-based pay and a multi-year vesting schedule. For investors, the award may modestly increase potential share dilution over the vesting period and signals the company’s approach to retaining and incentivizing current management during the interim leadership period. The 8-K does not disclose cash amounts or impact on total outstanding shares.